Phibro Animal Health Corp
PAHC Nasdaq· Pharmaceutical Preparations
Last close · Oct 23, 2026
$38.80
KIRA · Stoqly’s AI analyst, in plain words
- Phibro Animal Health Corp had $1.5B of revenue in fiscal 2026, up 17.1% on the year before. Over five years, revenue changed +12.7% a year on average.
- Its operating margin was 12.8%, up 4.3 pts: of every 100 in sales, about 13 is left after running the business.
- Phibro Animal Health Corp made $99.7M of net profit in fiscal 2026. From fiscal 2017 to 2026, diluted EPS grew 4.7% a year.
- Free cash flow was $9.9M in fiscal 2026, 0.6% of revenue.
- Phibro Animal Health Corp returned $19.5M to shareholders in fiscal 2026, 197% of free cash flow. The diluted share count rose 0.7%.
Market cap
$1.6B
P/E
16.0x
Revenue
$1.5B
Net income
$99.7M
Free cash flow
$9.9M
Operating margin
12.8%
Phibro Animal Health Corp in 30 seconds · fiscal 2026
Are sales growing?
+17.1%
Yes. Sales grew 17.1% last year.
Does it make a profit?
6.6%
A little. It keeps 6.6% of every sale as profit.
Does profit turn into cash?
0.6%
Partly. 0.6% of sales ends up as free cash.
How healthy are the accounts?
6 / 8
Mixed. It passes 6 of 8 health tests.
How is the share priced?
16.0x
One share costs 16.0 times its yearly profit per share.
What Phibro Animal Health Corp does
No business description yet.
- Fiscal year ends
- June 30, 2026
- Latest annual report
- 10-K · Aug 26, 2026
- Legal name
- PHIBRO ANIMAL HEALTH CORP
- CIK
- 0001069899
Phibro Animal Health Corp · PAHC
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $942M | $978M | $1.0B | $1.3B | $1.5B |
| Revenue growth | 13.1% | 3.8% | 4.1% | 27.4% | 17.1% |
| Net interest income | −$11.9M | −$15.3M | — | — | — |
| Gross margin | 30.3% | 30.5% | 30.8% | 30.9% | 33.8% |
| Operating margin | 8.4% | 7.3% | 5.2% | 8.5% | 12.8% |
| Net income | $49.2M | $32.6M | $2.4M | $48.3M | $99.7M |
| Net margin | 5.2% | 3.3% | 0.2% | 3.7% | 6.6% |
| Diluted EPS | $1.21 | $0.81 | $0.06 | $1.19 | $2.43 |
| Cash | |||||
| Cash from operations | $31.6M | $13.3M | $87.6M | $80.1M | $69.0M |
| Capital expenditure | $37.0M | $51.8M | $41.2M | $38.3M | $59.1M |
| Free cash flow | −$5.4M | −$38.5M | $46.4M | $41.8M | $9.9M |
| FCF margin | −0.6% | −3.9% | 4.6% | 3.2% | 0.6% |
| Dividends paid | $19.4M | $19.4M | $19.4M | $19.4M | $19.5M |
| Share count change | 0.0% | 0.0% | 0.0% | 0.4% | 0.7% |
| Debt and strength | |||||
| Cash and short-term investments | $91.2M | $81.3M | $115M | $77.0M | $82.0M |
| Debt incl. finance leases | $288M | $356M | $312M | $632M | — |
| Shareholders' equity | $262M | $283M | $257M | $286M | $385M |
| Net debt / EBITDA | 1.8x | 2.6x | 2.2x | 3.6x | — |
| Current ratio | 3.0x | 3.3x | 2.9x | 2.8x | 3.0x |
| Interest coverage | 6.2x | 3.8x | 2.3x | 3.0x | 4.2x |
| Returns and quality | |||||
| Return on capital | 11.7% | 8.4% | 7.6% | 9.3% | — |
| Return on equity | 19.6% | 12.0% | 0.9% | 17.8% | 29.7% |
| Return on tangible equity | 33.8% | 18.7% | 1.5% | 25.5% | 33.8% |
| Piotroski F-score | 5 | 5 | 6 | 5 | 6 |
| Altman Z'' | 4.5 | 4.6 | 4.2 | 4.0 | 4.7 |
Insiders bought, 12 months
$0.3M
1 insider
Insiders sold, 12 months
$28.6M
2 insiders
Of sales under plans
100%
$28.6M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Phibro Animal Health Corp · PAHC
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $38.80 a share, the company is worth $1.6B: 16.0 times its earnings of the last four quarters.
Source: SEC EDGAR XBRL filings (CIK 0001069899). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.